FDA, LDTs, and COVID-19: Interactions, Policy Shifts, and Key Issues (2020-2023) FDA, LDTs, and COVID-19 policy analysis covering three phases of LDT oversight during the pandemic: initial EUA-based enforcement discretion (early 2020), HHS blocking mandatory premarket review (Aug 2020-Nov 2021), and FDA's restoration of EUA-first posture (Nov 2021-2023). Includes detailed timeline, document index, and quantitative markers drawn primarily from GAO-22-104266 and FDA policy guidance. ai file regulatory ldts _AI_COVID19_LDTs_FDA_Policy_Report.md regulatory/ldts/_AI_COVID19_LDTs_FDA_Policy_Report.md 2026_03_01 Created by ChatGPT Pro 5.2 Extended during archive preparation. **NOT HUMAN VERIFIED - MAY CONTAIN ERRORS** Detailed analysis of FDA policy actions, enforcement discretion shifts, and LDT oversight during COVID-19 (2020-2023), synthesizing GAO-22-104266, FDA COVID test policy guidance (7th edition), HHS rescission statements, and CDC LOCS alerts. Prompt not included. ldts, fda, covid-19, eua, laboratory-developed-tests, enforcement-discretion md CC BY 4.0 - https://creativecommons.org/licenses/by/4.0/ 4257 7034 gfile-url xfile-github-download-url pdf-gdrive-url pdf-github-url github-markdown-url github-markdown-download-url web-pdf-url web-slides-url youtube-url web-url